Hang in there!!, page-41

Hey everyone, following this company for some time but never really invested.

With the new executives on board, my interest has increased.

Saying that, I held myself back given some previous attempts by other companies.

Opthotech's Fovista, even though it was different (Anti-PDGF) therapy in combination with Lucentis and Eyelea...It failed to show any improvement in its P3 trials even though there was a lot of excitement around it at the time. Knowing a bit about this market, I know its extremely hard to show improvements in visual acuity in wAMD given mono therapies do quite a decent job (so the bar is high).

Additionally, P2 data from Fovista combination trial with Lucentis was very strong. In this 24 weeks study, patients who received both Fovista (1.5 mg) and Lucentis improved with an average of around 10 letters after 24 weeks opposed to 6.5 letters for those who received just Lucentis.

Sadly it wasn't replicated in P3.

I am sure many investors must have asked the same question, can anyone share their views on the same.

Thanks